ImmunoCellular Therapeutics Ltd : ImmunoCellular Therapeutics' Brain Cancer Technology Receives Important Japanese Patent Allowance
07/10/2012| 07:05am US/Eastern
Recommend:
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular Therapeutics" or the
Company") (NYSE MKT: IMUC), a biotechnology company focused on the
development of novel immune-based cancer therapies, announced the
allowance of a Japanese patent relating to a technology for the
treatment of brain cancer for which the Company holds an exclusive,
worldwide license. The patent covers the treatment of brain cancer with
a combination of a dendritic cell based vaccine combined either before
or concurrently with the administration of chemotherapy. The Company
believes that in the treatment of cancer, particularly cancers of the
central nervous system such as glioblastoma multiforme (GBM), a dual
therapeutic approach that includes the administration of a dendritic
cell-based cancer vaccine combined with a regimen of chemotherapy could
substantially enhance the clinical efficacy of treatment.
"The strengthening of our world-wide intellectual property protection
for the treatment and detection of cancers further supports our
developmental efforts and enhances our ability to license or partner our
immunotherapeutic platforms," said Manish Singh, Ph.D. President and CEO
of ImmunoCellular Therapeutics. "It is with this in mind that we
continue to pursue opportunities to solidify our intellectual property
on a global scale."
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage
company that is developing immune-based therapies for the treatment of
brain and other cancers. The Company has commenced a Phase II trial of
its lead product candidate, ICT-107, a dendritic cell-based vaccine
targeting multiple tumor-associated antigens for glioblastoma. To learn
more about the Company, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements that are
subject to a number of risks and uncertainties, including the risk that
the Japanese patent may not provide commercially significant protection
for any of the Company's products. Additional risks and uncertainties
are described in IMUC's most recently filed SEC documents, such as its
most recent annual report on Form 10-K, all quarterly reports on Form
10-Q and any current reports on Form 8-K. IMUC undertakes no obligation
to publicly update or revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
For ImmunoCellular Therapeutics, Ltd.
CEOcast, Inc.
James
Young, 212-732-4300
Investor Relations
jyoung@ceocast.com
© Business Wire 2012
Recommend :
